Failed - Adjourned - HouseElections, ConstitutionalAmendmentsAnd IntergovernmentalAffairs Committee

Cantrell (D) Additional Authors: Burch (D);Wayne (D);Jenkins (D);Marzian (D);Graham (D);Owens (D);Donohue (D);Scott (D)

Pricing and Payment - Industry, Medicaid Use and Cost - Rx Drugs

Non-binding resolution, encourages the United States Congress to pass legislation that permits the United States Centers for Medicare and Medicaid Services (CMS) to negotiate with pharmaceutical companies for fair and reasonable prices on prescription drugs.

Non-binding resolution encouraging Medicare and Medicaid negotiation

Pending - Assembly HealthAnd Senior Services Committee

Pricing and Payment - Industry, Other Prescription Drug Measures

Urges Congress and President to require federal government to negotiate Medicare prescription drug prices.

Non-binding resolution encouraging Medicare negotiation

Pending - AssemblyFinancial InstitutionsAnd Insurance Committee

McKeon (D) Additional Authors: Coughlin (D)

Urges Congress and President to require the federal government to negotiate Medicare prescription drug prices.

Non-binding resolution encouraging Medicare negotiation

Pending - Carryover - Assembly HealthAnd Senior Services Committee

Urges Congress and the President to require the federal government to negotiate Medicare prescription drug prices.

Non-binding resolution encouraging Medicare negotiation

Failed - Adjourned -Postponed Indefinitely

Aguilar (D) Additional Authors: Lontine (D)

Concerns wholesale importation of pharmaceuticals from Canada for resale to Colorado residents.

Order the State Departament to design a wholesale importation program that addresses the requirements of 21 U.S.C. sec. 384

Failed - Adjourned - House HealthAnd Welfare Committee

Creates and provides for a state prescription drug importation program.

Create the Canadian Prescription Drug Importation Program pursuant to 21 U.S.C. 384

Failed - Adjourned - Senate HealthAnd Welfare Committee

Non-binding joint resolution, requests a study concerning the prospective establishment of a state prescription drug importation program.

Non-binding resolution urging a study on the prospective establishment of a State program for importation of prescription drugs from Canada

Allows Maine residents to personally import medications as permitted under the federal food, drug, and cosmetic act.

Pricing and Payment - Industry, Access, Safety and Errors - Rx Drugs

Authorizes the purchase of prescription drugs from canada.

Under the Federal Food, Drug, and Cosmetic Act, the importation of unapproved new prescription drugs, including foreign-made versions of prescription drugs that have been approved by the federal FDA, is prohibited. However, the FDA has developed guidance that allows the personal importation of certain drugs. This bill, using the guidance developed by the Food and Drug Administration, enacts the Maine Pharmaceutical Drug Safety Act to allow an individual in Maine to import prescription drugs from Canada or certain member countries of the European Union for use by that individual or a member of that individual's immediate family. The country from which the prescription drug is to be imported must meet specific criteria regarding regulation of its pharmacies and pharmacists, as determined by the United States Secretary of State. The prescription drug to be imported must also meet specific requirements, importation of controlled substances and prescription drugs for sale or resale is specifically prohibited.

Under the Federal Food, Drug, and Cosmetic Act, the importation of unapproved new prescription drugs, including foreign-made versions of prescription drugs that have been approved by the federal FDA, is prohibited. However, the FDA has developed guidance that allows the personal importation of certain drugs. This bill, using the guidance developed by the Food and Drug Administration, enacts the Maine Pharmaceutical Drug Safety Act to allow an individual in Maine to import prescription drugs from Canada or certain member countries of the European Union for use by that individual or a member of that individual's immediate family. The country from which the prescription drug is to be imported must meet specific criteria regarding regulation of its pharmacies and pharmacists, as determined by the United States Secretary of State. The prescription drug to be imported must also meet specific requirements, importation of controlled substances and prescription drugs for sale or resale is specifically prohibited.

Pricing and Payment - Industry, Access, Safety and Errors - Rx Drugs

Authorizes the purchase of prescription drugs from canada.

Establishes a state-law based process related to the purchase of prescription drugs from Canada.

Pending - Joint Committee on Health CareFinancing

Establishes a state-law based process related to the purchase of prescription drugs from Canada.

Failed - Adjourned - HouseEconomic Development Committee

Pricing and Payment - Industry, Clinical Trials and Right to Try, Other Prescription Drug Measures

Provides that the state department of health and senior services ''shall conduct a study regarding the processes by which the state may import certain prescription drugs from other countries for eventual consumption by Missouri consumers.''

Montanans to Purchase Prescription Drugs In Canada

Pricing and Payment - Industry, Access, Safety and Errors - Rx Drugs

Permits Montanans to purchase prescription drugs in Canada, relates to health care services.

Pending - Assembly ConsumerAffairsAndProtection Committee

Englebright (D) Additional Authors: Ryan (D)

Relates to consumer protection from prescription drug re-importation and unlawful practices and enforcement and penalties.

Pending - Assembly ConsumerAffairsAndProtection Committee

Englebright (D) Additional Authors: Ryan (D)

Relates to consumer protection from prescription drug re-importation and unlawful practices and enforcement and penalties.

Failed - Adjourned - Senate HealthAnd Human Services Committee

Requires the Oklahoma Health Care Authority to submit to HHS no later than August 2018, an application for the approval of a program to allow for the importation of prescription drugs from Canada into the state under the provisions of federal law, including certification by the HHS Secretary that ""�'importation of Canadian prescription drugs will pose no additional risk to the public's health and safety and result in a significant reduction in the cost of covered products."" The OK Health Care Authority shall study how to gain federal approval for the state to import drugs by implementing a pilot to reduce prescription drug costs for Oklahoma consumers and state agencies. The study will include: a plan for operating the prescription pilot drug program, a plan to ensure that drugs under the prescription drug importation program meet federal and state standards for safety and effectiveness, examples of five to seven highly prescribed drugs with a large cost differential between Canadian and U.S. average prices whose importation will create significant consumer savings (with exclusions for biologics, infused or injectable products or controlled substances), and an estimate of the total potential consumer and state agency savings through importation. [Updated 3/5/2018]

Importing Pharmaceuticals from a Foreign Country

Failed - Adjourned - HousePublic Health Committee

Relates to importing pharmaceuticals from a foreign country.

Thurston (R) Additional Authors: Henderson (R)

Pricing and Payment - Industry, Insurance/Coverage - Rx Drugs

Requires the Department of Health to design a wholesale Canadian prescription drug importation program, apply for approval of the program by the Secretary of the U.S. Department of Health and Human Services, and, if the drug importation program is approved, to implement the provisions of the program. The state-run prescription drug importation program would import select, higher-cost drugs that are already licensed for sale in Canada, where sponsors estimate ''prescription drugs cost 30 percent less than in the United States.'' whole-sale importation program

Pricing and Payment - Industry, Other Prescription Drug Measures

Requires the Department of Health to study and report on prescription drug importation fir use by state residents.

Ashe (D) Additional Authors: Lyons (D);Ayer (D);Pearson (P);Sirotkin (D)

Pricing and Payment - Industry, Other Prescription Drug Measures, Cost Sharing and Deductibles - Consumers

Relates to the wholesale importation of prescription drugs into Vermont. Creates a wholesale importation program to purchase high-cost drugs through authorized wholesalers, who will purchase the drugs in Canada and make them available to Vermonters through an existing supply chain that includes local pharmacies. The bill requires Vermont's Agency for Human Services, in consultation with stakeholders and the federal government, to design and submit an importation proposal to the state legislature on or before Jan. 1, 2019 and further requires the agency to submit its proposal to the federal government on or before July 1, 2019, for final approval. The importation program must be operational within six months of approval of the financing strategy, certification, and federal government sign-off. Also addresses the impact of prescription drug costs on health insurance premiums. [Updated 5/7/2018]

State Administered Wholesale Drug Importation Program

Failed - Adjourned - House HealthAnd Human Resources Committee

Creates a state-administered wholesale drug importation program. Gives the state authority to designate a state agency to function as a drug wholesaler to import pharmaceuticals from Canada to providedrugs to West Virginians, while only importing ''those prescription pharmaceuticals expected to generate substantial savings for West Virginia's consumers.''

Pending - Senate Health, Human ServicesAnd Senior Citizens Committee

Pricing and Payment - Industry, Other Prescription Drug Measures

Prohibits excessive charges for drugs developed by publicly funded research. ''If a drug, biologic, or other health care technology approved by the federal Food and Drug Administration was developed, partially or entirely, through research and development that is directly or indirectly supported by the federal or State government, it shall be unlawful for any person to sell, offer to sell, or advertise for sale the drug, biologic, or technology to any purchaser in this State at a unit price that is greater than the benchmark unit price'' established in this section, or that constitutes discriminatory pricing. The benchmark unit price is the lowest price charged to countries in the Organization for Economic Co-Operation and Development for the same drug, biologic, or technology, that have the largest gross domestic product with a per capita income that is not less than half that in the United States. [updated 2/5/2018]

Price safeguards for publicly-funded drugs

Prohibits discriminatory pricing for drugs partially or entirely supported with federal funds, using OECD as benchmark

Pricing and Payment - Industry, Other Prescription Drug Measures

Requires each manufacturer of a prescription drug that has a wholesale acquisition cost of $10,000 or more annually or per course of treatment, to file a disclosure report on the costs for each qualifying drug to the Office of Statewide Health Planning and Development. Requires the Office to issue a report to the Legislature outlining the information in the manufacturer's report and to post the report on its Internet Web site. Requires the Office to convene an advisory workgroup to develop a reporting form. Relates to reports confidentiality. [Filed 2015, final action in 2016]

Manufacturers of drugs with wholesale prices of 10,000 or more per year or treatment shall report R&D costs, clinical trials costs, subsidies

Pending - Carryover - Assembly Health Committee

Pricing and Payment - Industry, Other Prescription Drug Measures

Requires each manufacturer of a prescription drug that has a specified wholesale acquisition cost to file a report on the costs for each qualifying drug to the Office of Statewide Health Planning and Development. Requires the Office to issue a report to the Legislature outlining the information in the manufacturer's report and to post the report on its Internet Web site. Requires the Office to convene an advisory workgroup to develop a form for such reporting requirements.

Manufacturers of drugs with wholesale prices of 10,000 or more per year or treatment shall report R&D costs, clinical trials costs, subsidies

Failed - Adjourned -Postponed Indefinitely

Roberts (D) Additional Authors: Donovan (D)

Establishes the Diabetes Drug Pricing Transparency Act, requires the State Board of Health to compile a list of prescription insulin drugs along with the wholesale acquisition cost of each drug and post such list on its website, requires the State Board to prepare a report form to be completed by drug manufacturers of prescription drugs as appears on the compiled list, requires pricing reports to be submitted by insurers issuing health coverage plans, makes appropriations.

Manufactures of selected diabetes drugs shall disclose the aggregate amount of R&D cost atributable to diabetes drugs

Drug Production Costs Transparency Requirements

Failed - Adjourned -Postponed Indefinitely

Ginal (D) Additional Authors: Kefalas (D);Salazar (D);Buckner (D);Aguilar (D);Lee (D);Newell (D);Vigil (D);Hullinghorst (D);Roberts (R);Lontine (D)

Concerns a requirement that drug manufacturers report production costs for certain high-cost prescription drugs.

Manufacturers of drugs with wholesale prices of 50,000 or more per year or treatment shall report R&D costs, clinical trials costs, subsidies

Joint Insurance and Real Estate Additional Authors: Mushinsky (D);Looney (D);Gentile (D);Rojas (D);Scanlon (D);Kennedy (D);Winkler (D);Young (D)

Pricing and Payment - Industry, Insurance/Coverage - Rx Drugs, Pharmacy Benefit Managers (PBM)

Requires manufacturers to disclose net drug cost after rebates and to inform the state Office of Health Strategy when a company has submitted a drug approval application to the US Food and Drug Administration, requires disclosing price increase justifications to the Office, which must be posted on the state website. Requires the Office of Health Strategy to annually list the top 10 drugs whose wholesale acquisition cost has increased by 25 percent and that represent substantial state spending. Imposes additional disclosure and reporting requirements on pharmacy benefits managers, health carriers, pharmaceutical manufacturers, the Office of Health Strategy and the Insurance Department concerning prescription drug rebates and the cost of prescription drugs.

Manufacturers of a list of up to 10 drugs selected by price and public health importance shall report aggregate, company-level R&D costs

Concerns prescription drug cost transparency, explores options to help reduce the high costs of prescription drugs and educate the public and state agencies that pay for prescription drugs as to the costs of such drugs.

Manufacturers of every drug made available in Connecticut shall report R&D costs, clinical trials costs

Failed - Adjourned - House Public Health Committee

Pricing and Payment - Industry, Medicaid Use and Cost - Rx Drugs

Relates to prescription drug cost reporting, requires the office of the secretary of family and social services to identify any prescription drug under the Medicaid program for which the annual wholesale cost or the per course cost of treatment of the drug is at least $10,000, and directs the office to notify the manufacturer that the manufacturer is required to prepare a report on the drug to the drug utilization review board, Specifies requirements of the report.

Manufacturers of drugs under Medicaid with wholesale prices of 10,000 or more per year or treatment shall report R&D costs, clinical trials costs, subsidies

Failed - Adjourned - House HealthAnd Government Operations Committee

Bromwell (D) Additional Authors: Lewis R (D);Jackson (D);Hill (D);Hettleman (D);Fennell (D);Ebersole (D);Chang (D);Brooks (D);Barnes D (D);Atterbeary (D);Fraser-Hidalgo (D);Washington A (D);Wilson (D);Washington M (D);Miller A (D);Luedtke (D);Kelly A (D);Knotts (D);Korman (D);Proctor S (D);Sanchez (D);Young P (D);Young (D);Tarlau (D);Sydnor (D);Sample-Hughes (D);Platt (D);Patterson (D);Morales (D);Moon (D);McCray (D);Lisanti (D);Lierman (D);Lam (D);Krimm (D);Cullison (D);Clippinger (D);Dumais (D);Gaines (D);Jones A (D);Turner F (D);Vallario (D);Sophocleus (D);Rosenberg (D);Oaks (D);McIntosh (D);Frush (D);Howard (D);Hixson (D);Healey (D);Branch (D);Davis D (D);Barkley (D);Gutierrez (D);Haynes (D);Carr (D);Frick (D);Walker (D);Waldstreicher (D);Valderrama (D);Stein (D);Pena-Melnyk (D);Lafferty (D);Glenn (D);Conaway (D);Beidle (D);Barnes (D);Anderson (D);Kaiser (D);Jameson (D);Holmes (D);Barve (D)

Requires, on or before March 31 each year, the manufacturer of an expensive drug sold or offered for sale in the state to file with the Secretary of Health and Mental Hygiene a specified annual report, establishes the Drug Price Transparency Advisory Committee, requires a manufacturer of an expensive drug to file a notice with the Secretary before increasing a specified price or a specified cost by more than a specified percentage or amount during specified periods of time.

Manufacturers of drugs with wholesale prices of 2,500 or more per year or treatment shall report R&D costs, subsidies

Health Empowerment and Health Care Affordability

Pricing and Payment - Industry, Insurance/Coverage - Rx Drugs, Pharmacy Benefit Managers (PBM)

MA S 2202 - New Draft of

Transparency to prevent price gouging. Provides that the state Health Policy Commission (HPC) require testimony at annual cost trend hearings from PBMs & pharmaceutical manufacturers, to include ""factors underlying prescription drug costs and prices increases, the impact of manufacturer rebates, discounts and other price concessions on net pricing, the availability of alternative drugs or treatments and any other matters as determined by the commission. Also requires manufacturers to provide early notice relative to drugs and biologics in the development pipeline to HPC, hospitals, surgical centers and surcharge payors. Also HPC must ""conduct annual study of pipeline, generic and biosimilars that have significant impact on health expenditures."" PBMs/Manufacturers must report to the state: Wholesale acquisition cost (WAC) changes, company-level and product-specific R&D, price paid to acquire the drug (if applicable), 5-year WAC increase history, annual marketing and advertising expenditures, factors contributing to WAC changes. [Updated 12/27/2017]

Manufacturers and PBMs shall report aggregate, company-level and product-specific R&D costs, as required by an State commission. Information is keep secret.

Pending - Joint Committee onPublic Health

Tosado (D) Additional Authors: Balser (D);Walsh (D);Whelan (R);Ultrino (D);Muratore (R);Gentile (D);Heroux (D);DiZoglio (D);Decker (D);Cutler (D);Cantwell (D);Provost (D);Scibak (D);Kocot (D);Connolly (D)

Relates to cost control of pharmaceutical drug prices. Authorizes the state to appoint a commission to develop a list of the top 20 selling drugs in the state and other drugs based on an enumerated list of price and use factors. For each specified drug, manufacturers must provide a detailed set of reports including manufacturing and marketing costs, costs to public and private purchasers, and other specified factors. The Commission will promulgate regulations, violations may subject a manufacturer to penalties up to $100,000 for each failure to comply. [updated 8/15/17]

Manufacturers of drugs placed on a "critical prescription drug" list based on price, access and therapeutic criterias shall report R&D costs, subsidies

Health Empowerment and Health Care Affordability

Pricing and Payment - Industry, Insurance/Coverage - Rx Drugs, Pharmacy Benefit Managers (PBM)

MA S 2190 - New Draft of;MA S 2211 - New Draft see

Transparency to prevent price gouging. Provides that the state Health Policy Commission (HPC) require testimony at annual cost trend hearings from PBMs & pharmaceutical manufacturers, to include ""factors underlying prescription drug costs and prices increases, the impact of manufacturer rebates, discounts and other price concessions on net pricing, the availability of alternative drugs or treatments and any other matters as determined by the commission. Also requires manufacturers to provide early notice relative to drugs and biologics in the development pipeline to HPC, hospitals, surgical centers and surcharge payors. Also HPC must ""conduct annual study of pipeline, generic and biosimilars that have significant impact on health expenditures."" PBMs/Manufacturers must report to the state: Wholesale acquisition cost (WAC) changes, company-level and product-specific R&D, price paid to acquire the drug (if applicable), 5-year WAC increase history, annual marketing and advertising expenditures, factors contributing to WAC changes. [Updated 12/27/2017]

Manufacturers shall report "aggregate, company-level and product-specific" R&D costs, as required by a State commission

Relates to cost control of pharmaceutical drug prices. Authorizes the state to appoint a commission to develop a list of the top 20 selling drugs in the state and other drugs based on an enumerated list of price and use factors. For each specified drug, manufacturers must provide a detailed set of reports including manufacturing and marketing costs, costs to public and private purchasers, and other specified factors. The Commission will promulgate regulations, violations may subject a manufacturer to penalties up to $100,000 for each failure to comply. [updated 8/15/17]

Manufacturers of drugs with price increases shall report total R&D cost, clinical trials costs, subsidies

Pricing and Payment - Industry, Cost Sharing and Deductibles - Consumers

Promotes transparency and prevent price gouging of pharmaceutical drug prices.

Manufacturers of drugs with wholesale prices of 10,000 or more per year or treatment, with price increases, and 10 costliest drugs shall report R&D costs, clinical trials costs, subsidies

Pending - Joint Committee on Health CareFinancing

Pricing and Payment - Industry, Cost Sharing and Deductibles - Consumers

Promotes transparency and prevent price gouging of pharmaceutical drug prices.

Manufacturers of drugs with wholesale prices of 10,000 or more per year or treatment, with price increases, and 10 costliest drugs shall report R&D costs, clinical trials costs, subsidies

Transparency and Cost Control of Pharmaceutical Drug

Promotes transparency and cost control of pharmaceutical drug prices. Requires that a state commission ""shall develop a list of critical prescription drugs for which there is a substantial public interest in understanding the development of its pricing. In developing the list, the commission shall consider the following factors: (i) the cost of the drug to public health care programs, including the office of Medicaid and the group insurance commission, (ii) the current cost of the drug in the commonwealth, (iii) the extent of utilization of the drug within the Commonwealth, and (iv) potential impact of the cost of the drug on the commonwealth's achievement of the statewide health care cost growth benchmark.'' If the commission ''determines that a prescription drug is significantly high, then the commission may set the maximum allowable price that the manufacturer can charge for that prescription drug that is sold for use'' in the state.

Manufacturers of drugs placed on a "critical prescription drug" list based on price and access criterias shall report R&D costs, subsidies

Failed - Adjourned - Senate HealthAnd Human ServicesFinanceAndPolicy Committee

Establishes the state Prescription Drug Cost Review and Rate Setting Act, creates a prescription drug cost review commission and rate-setting requirements, requires a report, appropriates money. Focuses on ""Excess costs"" defined as ''the cost of a prescription drug product that either: exceeds the therapeutic benefit relative to other therapeutic options or alternative treatments, or is not sustainable to public and private health care systems over a ten-year time period.'' Patented product manufacturers must notify the commission if they plan to increase the cost (WAC) of a patent-protected brand name drug by more than $10,000 during any 12-month period, or intend to introduce to market a brand name drug that has a cost of $30,000 per year or per course of treatment. Notice must be at least 30 days prior to effective date of the increase or introduction and must include a justification. Generic manufacturers must notify any increase of 25% or more than $300 during any 12-month period.

A drug cost review commision that reviews whether prices are excesive can take R&D, as shown in tax fillings, into consideration

Failed - Adjourned - House HealthAnd Human Services Reform Committee

Democratic–Farmer–Labor

MN S 2947 - Companion

Requires cost disclosure and transparency by drug manufacturers for qualifying prescription drugs. ''to make information available to the public about the cost of ultra-high-priced pharmaceuticals ($10,000 or more annually) in order to make pharmaceutical pricing as transparent as the pricing in other sectors of the health care industry."" Requires annual cost reporting on the most expensive drugs that would allow policy makers, government agencies, and others to understand costs for these important products.

Manufacturers of drugs with wholesale prices of 10,000 or more per year or treatment shall report R&D costs, clinical trials costs, subsidies

Failed - Adjourned - SenateFinance Committee

Democratic–Farmer–Labor

MN H 2526 - Companion

Requires cost disclosure and transparency for qualifying prescription drugs, with a wholesale acquisition cost (WAC) of $1,000 or more annually. Declares that ''the legislature finds that there should be annual cost reporting on the most expensive drugs that would allow policymakers, government agencies, and others to understand costs for these important products.''

Manufacturers of drugs with wholesale prices of 1,000 or more per month or treatment shall report R&D costs, clinical trials costs, subsidies

Reporting of Information Relating to Prescription Drugs

Requires Rx manufacturers to reporting of certain information on drugs with a wholesale price of at least $10,000 or an annual price increase of 25%, relating to the manufacturer's cost associated with their prescription drugs.

Manufacturers of drugs with wholesale prices of 10,000 or more per year or treatment or with price increases shall report R&D costs, clinical trials costs, subsidies

Prescription Drug Review Commission Establishment

Pending - Assembly HealthAnd Senior Services Committee

Moriarty (D) Additional Authors: Danielsen (D)

Establishes the NJ Prescription Drug Review Commission, requires prescription drug production costs be reported. Specifically, ''The commission shall develop a list of critical prescription drugs made available in New Jersey for which there is a substantial public interest in understanding the development of pricing for the drugs.'' Reports will the cost of the drug to public health care programs including, the Medicaid and NJ FamilyCare programs, as well as retail or insurance related prices. Also includes extent of product use and the availability and cost of comparable or therapeutically equivalent courses of treatment. It will ''require the manufacturer of the drug to report: total cost of production, and approximate cost of production per dose, marketing and advertising costs for the drug, research and development costs of the drug, including: (a) R & D paid with public funds, (b) after-tax research and development costs paid by the manufacturer, and (c) research and development costs paid by third parties, and other financial factors. ''If the commission determines that the cost of a prescription drug is excessively high, the commission may set the maximum allowable price that the manufacturer can charge for that prescription drug when sold for use in New Jersey.'' [Added 1/22/2018]

Manufacturers of drugs placed on a "critical prescription drug list" based on price, access and therapeutic criterias shall report R&D costs, subsidies

Pending - Senate Health, Human ServicesAnd Senior Citizens Committee

Pricing and Payment - Industry, Other Prescription Drug Measures

Establishes a state Prescription Drug Review Commission, requires production costs be reported for certain prescription drugs. ''The commission shall develop a list of critical prescription drugs made available in New Jersey for which there is a substantial public interest in understanding the development of pricing for the drugs. In developing the list, the commission shall consider the following factors: (1) the cost of the drug to public health care programs including, but not limited to, the Medicaid and NJ FamilyCare programs, (2) the current cost of the drug in the State, (3) the extent of utilization of the drug within the State, (4) the availability and cost of comparable or therapeutically equivalent courses of treatment, (5) the rate at which the drug is deemed to produce successful outcomes when used to treat the conditions for which it is most commonly prescribed, and (6) such other objectively quantifiable factors as the commission determines to be relevant to evaluating the significance of the availability of the drug in New Jersey.'' For each prescription drug that the commission places on the critical prescription drug list pursuant to subsection a. of this section, the commission shall require the manufacturer of the drug to report the following information to the commission: (1) total cost of production, and approximate cost of production per dose, (2) research and development costs of the drug, including: (a) research and development costs that are paid with public funds, (b) after-tax research and development costs paid by the manufacturer, and (c) research and development costs paid by third parties, (3) marketing and advertising costs for the drug, apportioned by marketing activities that are directed to consumers, marketing activities that are directed to prescribers, and the total cost of all marketing and advertising that is directed primarily to New Jersey consumers and prescribers, (4) the prices for the drug that are charged to purchasers outside the United States, by country, for a representative set of countries determined by the commission, (5) prices charged to typical New Jersey purchasers, including, but not limited to, pharmacies, pharmacy chains, pharmacy wholesalers, or other direct purchasers, and (6) true net typical prices charged to prescription drug benefit managers for distribution in New Jersey. [Updated 2/5/2018]

Manufacturers of drugs placed on a "critical prescription drug list" based on price, access and therapeutic criterias shall report R&D costs, subsidies

Pending - Assembly HealthAnd Senior Services Committee

NJ S 3088 - Identical

Establishes Prescription Drug Review Commission, requires transparency by manufacturers, including production costs to be reported for certain high-cost prescription drugs.

Manufacturers of drugs placed on a "critical prescription drug list" based on price, access and therapeutic criterias shall report R&D costs, subsidies

Pending - Assembly HealthAnd Senior Services Committee

Establishes Prescription Drug Review Commission, requires transparency by manufacturers, including production costs to be reported for certain high-cost prescription drugs.

Manufacturers of drugs placed on a "critical prescription drug" list based on price, access and therapeutic criterias shall report R&D costs, subsidies

McDonald J (D) Additional Authors: Ortiz (D);Morinello (R);Walsh (R)

Relates to prescription drug cost transparency.

Manufacturers of drugs with wholesale prices of 1,000 or more per month or with price increases shall report R&D costs, clinical trials costs, subsidies

McDonald J (D) Additional Authors: Ortiz (D);McDonald J (D);Morinello (R);Walsh (R)

Relates to prescription drug cost transparency.

Manufacturers of drugs with wholesale prices of 1,000 or more per month or with price increases shall report R&D costs, clinical trials costs, subsidies

Requires prescription drug cost transparency. The manufacturer of a pharmaceutical drug that has a wholesale acquisition cost of one thousand dollars for a thirty day supply or cumulative price increase of three times the consumer price index in a 3-month period, shall file a report

Manufacturers of drugs with wholesale prices of 1,000 or more per month shall report R&D costs, clinical trials costs, subsidies

Enacts the pharmaceutical cost transparency act of 2015 requiring prescription drug manufacturers to file a report disclosing certain financial information pertaining to prescription drugs which have a wholesale acquisition cost of $10,000 or more annually or per course of treatment.

Manufacturers of drugs with wholesale prices of 10,000 or more per year or treatment shall report R&D costs, clinical trials costs, subsidies

Diaz Ru (D) Additional Authors: Perkins (D)

Enacts the Pharmaceutical Cost Transparency Act of 2015 requiring prescription drug manufacturers to file a report disclosing certain financial information pertaining to prescription drugs which have a wholesale acquisition cost of a certain sum or more annually or per course of treatment.

Manufacturers of drugs with wholesale prices of 10,000 or more per year or treatment shall report R&D costs, clinical trials costs, subsidies

Pricing and Payment - Industry, Access, Cost Sharing and Deductibles - Consumers

Relates to prescription drug cost transparency. Requires manufacturers of a brand and generic medication that is made available in New York state to file a report annually on pharmaceutical costs for products with a price of $1,000 or more for a 30 day supply or an increased prices within a 3-month period of 3 times the CPI (consumer price index) with detailed statistics on each of 15 segments of actual costs including research, clinical trials, production, marketing, direct-to-consumer advertising, prescriber education, beginning in 2017 Resulting ''information shall be made publicly available on the department's website.'' [Added 5/16/2016]

Manufacturers of drugs with wholesale prices of 1,000 or more per month shall report R&D costs, clinical trials costs, subsidies

Enacts the pharmaceutical cost transparency act of 2015 requiring prescription drug manufacturers to file a report disclosing certain financial information pertaining to prescription drugs which have a wholesale acquisition cost of $10,000 or more annually or per course of treatment.

Manufacturers of drugs with wholesale prices of 10,000 or more per year or treatment shall report R&D costs, clinical trials costs, subsidies

Diaz Ru (D) Additional Authors: Perkins (D)

Enacts the pharmaceutical cost transparency act of 2015 requiring prescription drug manufacturers to file a report disclosing certain financial information pertaining to prescription drugs which have a wholesale acquisition cost of $10,000 or more annually or per course of treatment.

Manufacturers of drugs with wholesale prices of 10,000 or more per year or treatment shall report R&D costs, clinical trials costs, subsidies

Failed - Adjourned - House Health Committee

Collins (R) Additional Authors: Saine (R);Bell J (R);Hanes (D)

Cost and price transparency. Requires manufacturers of pharmaceutical drugs to report cost and utilization information. For seven specified categories of drugs (including cancer and all biologics) brand manufacturers would report: (1) Total costs derived in the production of the drug, (2) Average wholesale cost including increases by month over a 5-year period, (3) Total research and development costs paid by the manufacturer, (4) Total administrative costs, marketing and advertising costs for the promotion of the drug, and costs associated with direct to consumer coupons and amount redeemed, (5) Total profit as represented in total dollars and a percentage of total company profit derived from the sale of the drug, and (6) Total amount of financial assistance the manufacturer has provided through patient prescription assistance programs.

Manufacturers of every drug made available in North Carolina shall report cost R&D costs

Failed - Adjourned - Senate Health Care Committee

Steiner Hayward (D) Additional Authors: Steiner Hayward (D);Nosse (D)

Requires prescription drug manufacturer to report to Department of Consumer and Business Services prices and increases in prices of manufacturer's prescription drugs sold in the state, requires manufacturer to provide justification for increase in price greater than a specified percent for prescription drugs sold in the state longer than a specified number of months, requires department to order manufacturer to refund excessive price increases to purchasers of prescription drugs.

Manufacturers of drugs with price increases shall report total R&D cost

Biologics and Biosimilars, Pricing and Payment - Industry

Price and cost transparency: Requires manufacturer of prescription drug with annual wholesale acquisition cost of $10,000 or more, or with wholesale acquisition cost of $10,000 or more per course of treatment, to file annual report with Oregon Health Authority on costs associated with prescription drug for previous calendar year.

Manufacturers of drugs with wholesale prices of 10,000 or more per year or treatment shall report R&D costs, clinical trials costs, subsidies

Failed - Adjourned - Joint Committee on Ways and Means

Creates Oregon Premium Protection Program in Department of Consumer and Business Services and establishes Oregon Premium Protection Fund, requires pharmaceutical manufacturer to pay to department cost of prescription drug that exceeds specified threshold, requires department to use payments to reimburse insurers, third party administrators, Public EmployeesΓÇÖ Benefit Board, Oregon Educators Benefit Board, health care service contractors and other entities for incurred costs of drug that exceeds threshold.

Manufacturers of drugs with an introductory wholesale prices of 12,000 or more per year shall report R&D costs, clinical trials costs

Pending - Carryover - House Insurance Committee

DeLuca (D) Additional Authors: Cohen (D);Acosta (D);McNeill (D);Grove (R);Costa D (D);Moul (R);Mahoney (D);Harkins (D);Cox (R);Pickett (R);Thomas (D);Hennessey (R);Parker D (R)

Cost and price transparency: Amends the state insurance act, provides for pharmaceutical cost transparency. Establishes that for any ''prescription drug with an average wholesale price of $5,000 or more annually or per course of treatment, a health insurance policy or government program providing benefits for prescriptions shall not be required to provide the benefits if the manufacturer of the prescription drug has not filed a report on the drug'' that details the costs of production, research and development, clinical trials and regulatory requirements, marketing and other expenses.

Manufacturers of drugs with wholesale prices of 5,000 or more per year or treatment shall report R&D costs, clinical trials costs, subsidies

DeLuca (D) Additional Authors: Cohen (D);Acosta (D);McNeill (D);Grove (R);Costa D (D);Moul (R);Mahoney (D);Harkins (D);Cox (R);Pickett (R);Thomas (D);Hennessey (R);Parker D (R)

Cost and price transparency: Amends the state insurance act, provides for pharmaceutical cost transparency. Establishes that for any ''prescription drug with an average wholesale price of $5,000 or more annually or per course of treatment, a health insurance policy or government program providing benefits for prescriptions shall not be required to provide the benefits if the manufacturer of the prescription drug has not filed a report on the drug'' that details the costs of production, research and development, clinical trials and regulatory requirements, marketing and other expenses.

Manufacturers of drugs with wholesale prices of 5,000 or more per year or treatment shall report R&D costs, clinical trials costs, subsidies

Pending - House Corporations Committee

Fellela (D) Additional Authors: Ucci (D);Serpa (D);Azzinaro (D);Messier (D)

Cost transparency for high-cost pharmaceuticals: Would require the Executive Office of Health and Human Services (""EOHHS"") to create a critical prescription drug list where there is a substantial public interest in understanding the development of its pricing. If a prescription drug is placed on the critical prescription drug list, the manufacture of such prescription drug must report certain information to EOHHS. This act would take effect on January 1, 2017.

Manufacturers of drugs placed on a "critical prescription drug" list based on price and access criterias shall report R&D costs, subsidies

Pending - Senate HealthAnd Human Services Committee

Coyne (D) Additional Authors: DiPalma (D);Archambault (D);Goldin (D);Satchell (D)

Pricing and Payment - Industry, Access, Cost Sharing and Deductibles - Consumers

Cost and price transparency: Would require the Executive Office of Health and Human Services (""EOHHS"") to create a critical prescription drug list where there is a substantial public interest in understanding the development of its pricing. If a prescription drug is placed on the critical prescription drug list, the manufacture of such prescription drug must report certain information to EOHHS. This act would take effect on January 1, 2017. [Added 3/1/2016]

Manufacturers of drugs placed on a "critical prescription drug" list based on price and access criterias shall report R&D costs, subsidies

Pending - Senate Health and Human Services Committee

Coyne (D) Additional Authors: Conley (D);Goldin (D);Satchell (D);Calkin (D)

Requires the Executive Office of Health and Human Services, EOHHS to create a critical prescription drug list where there is a substantial public interest in understanding the development of its pricing, requires if a prescription drug is placed on the critical prescription drug list, the manufacture of such prescription drug must report certain information to EOHHS, enables EOHHS to set maximum price limits on those drugs.

Manufacturers of drugs placed on a "critical prescription drug" list based on price and access criterias shall report R&D costs, subsidies

Pending - Senate Health and Human Services Committee

Coyne (D) Additional Authors: Conley (D);Goldin (D);Satchell (D);Calkin (D)

Requires the Executive Office of Health and Human Services, EOHHS to create a critical prescription drug list where there is a substantial public interest in understanding the development of its pricing, requires if a prescription drug is placed on the critical prescription drug list, the manufacture of such prescription drug must report certain information to EOHHS, enables EOHHS to set maximum price limits on those drugs.

Manufacturers of drugs placed on a "critical prescription drug" list based on price and access criterias shall report R&D costs, subsidies

Failed - Adjourned - House Health Committee

TN S 2442 - Same as

Relates to prescription drug cost transparency, authorizes the department of health to require certain prescription drug manufacturers to disclose price and cost information, authorizes the department of health to set maximum prices for certain prescription drugs. If the department of health determines that a prescription drug price is significantly high, then the department of health may set the maximum allowable price that the manufacturer can charge for that prescription drug'' in the state.

Manufacturers of drugs placed on a "critical prescription drug list" based on price and access criterias shall report R&D costs, subsidies

Failed - Adjourned - Senate CommerceAnd Labor Committee

TN H 2206 - Same as

Authorizes the Department of Health to ''develop a list of critical prescription drugs for which there is a substantial public interest in understanding the development of the drugs' pricing.'' require certain prescription drug manufacturers to disclose price in-state compared to prices in other countries, and cost of research, production, marketing information. If the department of health determines that a prescription drug price is significantly high, then it ''may set the maximum allowable price that the manufacturer can charge for that prescription drug that is sold for use in the state.''

Manufacturers of drugs placed on a "critical prescription drug list" based on price and access criterias shall report R&D costs, subsidies

International Pharmaceuticals Price Discrimination

Failed - Adjourned - House InternationalTradeAnd IntergovernmentalAffairs Committee

Price and cost transparency: provides for an interim study regarding international price discrimination in pharmaceuticals.

A joint interim committee on drug pricing shall consider R&D subsidies

Prescription Drug Manufacturer Cost Transparency

Failed - Adjourned - House Health Care Committee

Relates to requiring prescription drug manufacturer cost transparency.

Manufacturers of drugs placed on a list based based on State healthcare spending shall report R&D cost, clinical trials, subsidies

Hurst (D) Additional Authors: Plum (D);Edwards (D);Hope (D);Simon (D);Boysko (D);Krizek (D);Levine (D);Gooditis (D)

Pricing and Payment - Industry, Insurance/Coverage - Rx Drugs

Relates to prescription drug price transparency, requires every manufacturer of a prescription drug that is made available in the state and has a wholesale acquisition price of $10,000 or more for a single course of treatment to report to the State Health Commissioner no later than July 1 of each year information related to the cost of developing, manufacturing, and marketing the prescription drug.

Manufacturers of drugs with wholesale prices of 10,000 or more per treatment or with price increases shall report R&D costs, clinical trials costs, subsidies

Relates to prescription drug price transparency, requires every manufacturer of a prescription drug that is made available in the Commonwealth and has a wholesale acquisition price of $10,000 or more for a single course of treatment to report to the Commissioner no later than July 1 of each year information related to the cost of developing, manufacturing, and marketing the prescription drug.

Manufacturers of drugs with wholesale prices of 10,000 or more per treatment shall report R&D costs, clinical trials costs, subsidies

Relates to prescription drug price transparency, requires every manufacturer of a prescription drug that is made available in the Commonwealth and has a wholesale acquisition price of $10,000 or more for a single course of treatment to report to the Commissioner no later than July 1 of each year information related to the cost of developing, manufacturing, and marketing the prescription drug.

Manufacturers of drugs with wholesale prices of 10,000 or more per treatment shall report R&D costs, clinical trials costs, subsidies

Pending - Carryover - SenateEducationAnd Health Committee

Relates to prescription drug price transparency, requires every manufacturer of a prescription drug that is made available in the Commonwealth and has a wholesale acquisition price of $10,000 or more for a single course of treatment to report to the Commissioner no later than July 1 of each year information related to the cost of developing, manufacturing, and marketing the prescription drug.

Manufacturers of drugs with wholesale prices of 10,000 or more per year or treatment shall report R&D costs, clinical trials costs, subsidies

Failed - Adjourned - IndefinitelyPostponed

Pricing and Payment - Industry, Cost Sharing and Deductibles - Consumers

Addresses prescription drug cost transparency, requires the state to collect, verify, and summarize prescription drug pricing data provided by health insurance issuers and manufacturers. A manufacturer with a drug that increases more than 10% or $10,000 in a year must report for such drug, the time on the market, the generic or brand name status, pricing history in the US the previous five years, total financial assistance given by the manufacturer through assistance programs, rebates, and coupons, and an economic justification of the qualifying price increase for the covered drug. Any qualifying price increase for a covered drug must be announced 60 days before the change. Separately, each health insurance plan issuer must identify overall spending on prescription drugs and by the 25 most frequently prescribed drugs, the 25 costliest prescription drugs, with the information by the state Medicaid program, public employees' benefits board programs, and the individual, small group, and large group markets. All data submitted must be collected by a state-approved data organization and made publicly available on the office's web site, with reports due starting Nov. 1, 2017. Fines may be up to $1000 per day for non-compliance.

Manufacturers of drugs with wholesale prices of 10,000 or more per year or treatment or with price increases shall report R&D costs, clinical trials costs, subsidies

Failed - Adjourned - Senate Health & LongTerm Care Committee

Pricing and Payment - Industry, Insurance/Coverage - Rx Drugs

WA H 1541 - Companion

Addresses prescription drug cost transparency, requires the state to collect, verify, and summarize prescription drug pricing data provided by health insurance issuers and manufacturers. A manufacturer with a drug that increases more than 10% or $10,000 in a year must report for such drug, the time on the market, the generic or brand name status, pricing history in the US the previous five years, total financial assistance given by the manufacturer through assistance programs, rebates, and coupons, and an economic justification of the qualifying price increase for the covered drug. Any qualifying price increase for a covered drug must be announced 60 days before the change. Separately, each health insurance plan issuer must identify overall spending on prescription drugs and by the 25 most frequently prescribed drugs, the 25 costliest prescription drugs, with the information by the state Medicaid program, public employees' benefits board programs, and the individual, small group, and large group markets. All data submitted must be collected by a state-approved data organization and made publicly available on the office's web site, with reports due starting Nov. 1, 2017. Fines may be up to $1000 per day for non-compliance.

Manufacturers of drugs with wholesale prices of 10,000 or more per year or treatment or with price increases shall report R&D costs, clinical trials costs, subsidies

Pending - Carryover - Senate Health Care Committee

Pricing and Payment - Industry, Cost Sharing and Deductibles - Consumers

Addresses prescription drug cost transparency, requires the state to collect, verify, and summarize prescription drug pricing data provided by health insurance issuers and manufacturers. A manufacturer with a drug that increases more than 10% or $10,000 in a year must report for such drug, the time on the market, the generic or brand name status, pricing history in the US the previous five years, total financial assistance given by the manufacturer through assistance programs, rebates, and coupons, and an economic justification of the qualifying price increase for the covered drug. Any qualifying price increase for a covered drug must be announced 60 days before the change. Separately, each health insurance plan issuer must identify overall spending on prescription drugs and by the 25 most frequently prescribed drugs, the 25 costliest prescription drugs, with the information by the state Medicaid program, public employees' benefits board programs, and the individual, small group, and large group markets. All data submitted must be collected by a state-approved data organization and made publicly available on the office's web site, with reports due starting Nov. 1, 2017. Fines may be up to $1000 per day for non-compliance.

Manufacturers of drugs with wholesale prices of 10,000 or more per year or treatment or with price increases shall report R&D costs, clinical trials costs

Pharmaceutical Drug Cost and Utilization Transparency

Failed - Adjourned - House Health CareAnd Wellness Committee

Concerns pharmaceutical drug cost and utilization transparency.

Manufacturers of drugs with wholesale prices of 10,000 or more per year or treatment shall report R&D costs, clinical trials costs, subsidies

Jackson (D) Additional Authors: Davis P (R);Saviello (R);Gattine (D);Mastraccio (D);Vitelli (D);Lawrence (D);Bellows (D);Carson (D)

Summary This bill amends the Maine Pharmacy Act to require that a drug distributed in this State must be made available for sale in this State to a person seeking to develop an application for the approval of the drug under the Federal Food, Drug, and Cosmetic Act or the licensing of a biological product under the federal Public Health Service Act. It establishes disciplinary actions for noncompliance.

Manufacturers of certain drugs shall make them available to an eligible product developer for purposes of conducting testing

Syms (R) Additional Authors: Barton (R);Boyer (R);Finchem (R);Kern (R);Weninger (R)

Pricing and Payment - Industry, Pharmacy Benefit Managers (PBM)

Relates to prescription drug costs: Provides that a PBM (pharmacy benefits manager) or other entity that administers prescription drug benefits 'may not prohibit by contract a pharmacy or pharmacist from informing the patient that the patient may be able to procure a prescription medication at a lower cost, including by paying the cash price.'' (no 'gag' clauses) [Updated 4/16/2018]

PBMs cannot prohibit a pharmacy to disclose information on price of a drug or affordable alternatives to an insured

Encourages the United States Congress to investigate the increases in cost of generic prescription medications, urges the Food and Drug Administration to review federal regulations concerning generic pharmaceutical manufacturers.

Increases in Cost of Generic Prescription Medications

Encourages the United States congress to investigate the increases in cost of generic prescription medications, urges the food and drug administration to review federal regulations concerning generic pharmaceutical manufacturers.

Hernandez (D) Additional Authors: Chiu (D);Wood (D)

Requires pharmaceutical manufacturers to submit to public and private purchasers (including state agencies, health insurers, and pharmacy benefit managers) 90-day advance notification of price increases for prescription drugs currently on the market, including detailed information regarding the reasons and justification for such increases, as well as justification of launch prices for new drugs. Requires health insurers that file rate information to report specified cost information regarding covered prescription drugs, including generic drugs, brand name drugs, and specialty drugs. Requires reporting the percentage of the insurance premium attributable to prescription drugs.

Hernandez (D) Additional Authors: Leno (D);Hall (D)

Relates to EpiPen pricing. Urges the U.S. Food and Drug Administration (FDA)to reconsider its denial of approval for generic alternatives to the epinephrine auto-injector EpiPen. Urges the Congress of the United States to investigate the impact that Mylan NV's monopoly has had on price increases for EpiPen. Urges the Congress and the President of the United States to take action to limit the unrestrained ability of drug manufacturers to increase prices based on what the market can bear.

Failed - Adjourned - Assembly InactiveFile

Hernandez (D) Additional Authors: Chiu (D)

Pricing and Payment - Industry, Cost Sharing and Deductibles - Consumers

Rx Transparency: Requires a drug manufacturer to inform State purchasers, health care service plans, health insurers and chairs of specified legislative committees about increases of 10% or more in the wholesale acquisition cost of drugs and of the introduction to market of a prescription drug that has a wholesale acquisition cost of $10,000 or more annually or per course of treatment, and report specified information regarding the drug price. Requires health insurers that file rate information to report the 25 most frequently prescribed drugs and the average wholesale price for each drug and the 25 most costly drugs by total plan or insurer spending and the average wholesale price for each drug. Relates to submission of rate increases for all large group benefit plans. Failure to comply in 30 days may result in a civil penalty of $1,000 per day.

Concerns a prohibition against price gouging on certain prescription drugs.

Attorney General may require info on cost of producing a drug, circunstances and timming of the price increase

Failed - Adjourned -Postponed Indefinitely

Ginal (D) Additional Authors: Moreno (D);Jackson (D)

Pricing and Payment - Industry, Pharmacy Benefit Managers (PBM)

Concerns prescription drug price transparency, enacts the ""Colorado Prescription Drug Price Transparency Act of 2018"", which requires health insurers to submit to the commissioner of insurance information regarding drug prescription coverage, prescription drug manufacturers to notify health insurer, state purchased and pharmacy benefit management firms price increases and specify new speciality drugs on the market.

Report on the 25 costliest drugs and 25 drugs with the highest year-over-year cost increases

Failed - Adjourned -Postponed Indefinitely

Aguilar (D) Additional Authors: Lontine (D)

Concerns a prohibition against price gouging on certain prescription drugs.

Failed - Adjourned - Legislative Commissioner's Office

Joint Insurance and Real Estate Additional Authors: Looney (D)

Concerns the cost of prescription drugs and value-based insurance design, requires manufacturers of prescription drugs to disclose pricing information to the Insurance Commissioner, requires that certain insurance policies incorporate value-based insurance design, establishes a task force to study methods of controlling the cost of prescription drugs.

Montford (D) Additional Authors: Grimsley (R);Broxson (R);Powell (D);Gainer (R)

Relates to prescription drug pricing transparency, requires a pharmacist to inform a customer of a lower cost alternative to a prescription and of whether the customers cost-sharing obligation exceeds the retail price of the prescription, defines the term pharmacy benefit manager, requires a pharmacy benefit manager to register with the Office of Insurance Regulation.

Yarborough (R) Additional Authors: Magar (R);Renner (R);Baez (D);White (R)

Relates to prescription drug price transparency, requires the Agency for Health Care Administration to collect data on retail prices charged by pharmacies for the most frequently prescribed medicines, requires the agency to update its website monthly.

Relates to prescription drug price transparency, requires the Agency for Health Care Administration to collect data on the retail prices charged by pharmacies for the 300 most frequently prescribed medicine.

Guzzardi (D) Additional Authors: Demmer (R);Stadelman (D);Harris N (D);Cullerton T (D);Bush (D);Bertino-Tarrant (D);Willis (D);Welch (D);Tabares (D);Moylan (D);Mitchell C (D);Kifowit (D);Van Pelt (D);Moeller (D);Carroll (D);Castro (D);Aquino (D);Stuart (D);Stratton (D);Mah (D);Murphy L (D);Harper (D);Bennett (D);Ammons (D);Wallace (D);Smith (D);Fine (D);Evans M (D);Raoul (D);Hunter (D);Sandoval (D);Martinez (D);Collins J (D);Chapa-LaVia (D);Lightford (D);Silverstein (D);Lang (D);Flowers (D);Hernandez (D);Holmes (D);Koehler (D);Cassidy (D);McCann (R);Biss (D);Gabel (D);Lilly (D);Jones (D);Hutchinson (D);Zalewski (D);Steans (D);Riley (D);Currie (D)

Creates the Generic Drug Pricing Fairness Act, provides that a manufacturer or wholesale drug distributor shall not engage in price gouging in the sale of an essential off-patent or generic drug, provides that the Director of Healthcare and Family Services or Director of Central Management Services may notify the Attorney General of any increase in the price of any essential off-patent or generic drug under the Medical Assistance Program under the Public Aid Code or a State health plan.

Flowers (D) Additional Authors: Lilly (D);Jones T (D);Manley (D);Tabares (D);Welch (D)

Pricing and Payment - Industry, Insurance/Coverage - Rx Drugs

Amends the Food, Drug and Cosmetic Act, requires manufacturers of brand name or generic prescription drugs to notify State purchasers, health insurers, health care service plan providers, pharmacy benefit managers, and the General Assembly of specified increases in drug prices at least 60 days before such increase and the cost of specified new prescription drugs within 3 days after approval by the U.S. Food and Drug Administration.

Failed - Adjourned - HousePublic Health Committee

Relates to conducting a state prescription drug pricing study, urges the legislative council to assign to the interim study committee on public health, behavioral health, and human services the task of studying issues related to prescription drug price transparency by drug manufacturers in Indiana.

Report on the effect that significant price increases have on access

Pending - Carryover - House HealthAnd Human Services Committee

Health and Human Services Cmt

Pricing and Payment - Industry, Insurance/Coverage - Rx Drugs, Pharmacy Benefit Managers (PBM)

The Rx transparency act requires that PBMs contracting with the state (employee) health care benefits program act as a fiduciary and disclose any payment or benefit received for the dispensing of a prescription drug. The PBM would also disclose all financial and utilization information requested by the program. Any payment or benefit received by the PBM for the dispensing of a prescription drug will be passed-through in full to the state.

Pricing and Payment - Industry, Pharmacy Benefit Managers (PBM)

Relates to pharmacy benefit managers, provides for internet publication of formularies, provides for transparency reporting, provides for certain reportable aggregate data, provides for internet publication of the transparency report, provides for definitions, provides for the duties of the commissioner of insurance relative thereto, provides for confidentiality.

Pricing and Payment - Industry, Cost Sharing and Deductibles - Consumers

Prohibits a manufacturer or wholesale distributor from engaging in price gouging in the sale of an essential off-patent or generic drug.

Attorney General may require info on cost of producing a drug, circunstances and timming of the price increase

Failed - Adjourned - House HealthAnd Welfare Committee

Prohibits a manufacturer or wholesale distributor from engaging in unrestrained price increases in the sale of an essential off-patent or generic drug.

Attorney General may require info on cost of producing a drug, circunstances and timming of the price increase